Dengue Literature Review

Post-Dengue Syndrome

7 min read

Post-Dengue Syndrome

Overview

Post-dengue syndrome refers to the persistence of clinical symptoms beyond the acute febrile phase of dengue infection, lasting weeks to years after apparent recovery. Manifestations span musculoskeletal pain (myalgia, arthralgia, arthropathy), neurological and cognitive complaints (memory loss, dizziness, headache, palpitations), fatigue and asthenia, and less commonly alopecia, rash, and bleeding. Fatigue specifically is present in 24.4% of hospitalized patients at 2 months post-discharge (Singapore cohort, see Seet2007 - Post-Infectious Fatigue Syndrome in Dengue). The syndrome is substantially under-characterised relative to acute dengue and may have an autoimmune basis. A cross-cohort finding from two independent studies (Singapore and Cuba) is that acute illness severity — DF vs. DHF/DSS — does not predict who will develop post-acute sequelae; host factors (age, sex, immune genetics) are the dominant modifiers.

Key Points from Literature

  • In a Cuban adult cohort followed 2 years after the 2006 DENV-4 epidemic, 56.7% (55/97) of symptomatic patients (DF or DHF) still reported clinical manifestations. No sequelae were found among the 42 asymptomatic patients (see Garcia2009 - Long-term Clinical Symptoms Post-Dengue).
  • Most common symptoms at 2 years: muscle pain (30.2%), arthralgia (29.5%), asthenia (23.0%), hand weakness (22.3%), general malaise (20.1%), irritability and memory loss (19.4% each), palpitations (19.4%), dizziness (17.9%), arthropathy (17.3%).
  • Acute illness severity (DF vs DHF/DSS) did not predict development of sequelae (p = 0.086).
  • Persistent symptoms were strongly female-predominant (65.7% of women vs 36.7% of men, p = 0.008; 44/55 symptomatic individuals were female), mirroring the sex bias seen in autoimmune diseases.
  • Higher anti-dengue IgG titers were associated with persistent symptoms (p = 0.041).
  • The FcγRIIa-HH genotype, which impairs immune complex clearance, was significantly associated with sequelae (OR 2.83; see FcγRIIa Receptor).
  • Autoimmune markers were elevated in 76.9% of a symptomatic subset: IC and CRP in 42.3% each, ANA in 23.1% (see Autoimmunity in Dengue).
  • A history of multiple prior dengue infections was common among symptomatic individuals (21/26 had ≥1 prior infection; 12/26 had tetravalent history), suggesting cumulative infection burden may be a trigger.
  • All participants showed normal formal psychological and cognitive function despite subjective cognitive complaints.

Seet2007: Post-Infectious Fatigue in Singapore (2-month prospective)

Seet2007 - Post-Infectious Fatigue Syndrome in Dengue is the first prospective, systematic study of post-dengue fatigue — and the second post-dengue cohort study in this wiki after Garcia2009. n=127 hospitalized adults, National University Hospital Singapore, October–November 2005 DEN-1 outbreak; 2-month follow-up by validated Fatigue Questionnaire (FQ).

  • 24.4% (31/127) had significant post-infectious fatigue at 2 months — comparable in magnitude to other post-infectious syndromes, though lower than post-EBV (38–40%) and post-Q-fever (31%).
  • Dengue severity did not predict fatigue: DHF vs. DF showed no significant association (p = 0.855, OR 0.851). This directly replicates the severity-independence finding from Garcia2009 (DF vs. DHF, p = 0.086) in an independent cohort, country, and serotype.
  • Multivariate predictors of fatigue — all host factors, no virological factors:
    • Older age (OR 1.118; 95% CI 1.033–1.209; p = 0.006)
    • Female sex (OR 9.687; 95% CI 1.546–60.684; p = 0.015) — remarkably large effect
    • Presence of chills (OR 6.904; 95% CI 1.157–41.202; p = 0.034)
    • Absence of rashes (OR 38.462; 95% CI 1.292–58.824; p = 0.026)
  • No haematologic or biochemical parameter (WBC, platelets, liver enzymes, coagulation times) was associated with fatigue.
  • Proposed mechanism (speculative): dengue-induced CD4/CD8 ratio inversion and C3a/C5a cytokine overproduction → immune-mediated endothelial damage → interaction with hypothalamic–pituitary–adrenal axis → fatigue.

Cross-cohort comparison with Garcia2009:

FeatureSeet2007 (Singapore)Garcia2009 (Cuba)
SerotypeDEN-1 dominantDENV-4
n12797 (symptomatic subset: 55)
Follow-up2 months2 years
OutcomeFatigue (FQ ≥4)Multi-symptom sequelae (muscle pain, arthralgia, asthenia, cognitive, ANA, IC, CRP)
Severity → outcomeNot significant (p=0.855)Not significant (p=0.086)
Sex effectOR 9.687 for female (multivariate)65.7% women vs. 36.7% men (p=0.008)
Host factors identifiedAge, sex, chills, absence of rashesFcγRIIa-HH genotype, IgG titres, prior infection count

The convergence on severity-independence and female predominance across two independent cohorts from different countries, serotypes, and follow-up periods is the strongest cross-paper finding on post-dengue syndrome in this wiki.

Guzman2016: Post-acute complications and QoL (broader scope)

Guzman2016 extends the picture of post-dengue consequences beyond musculoskeletal/cognitive symptoms to include systemic complications documented in the literature (see Guzman2016 - Dengue Infection):

Quality of life at 6 months

In dengue survivors, at 6 months post-acute illness:

  • Weakness: 27.6%
  • Headache: 14.8%
  • Arthralgia: 10.6% Persistence at 2 years is independently confirmed across studies.

Neurological complications

  • Dengue encephalopathy: altered consciousness during or shortly after acute dengue; proposed mechanisms include cerebral oedema (from systemic vascular leakage), direct neurotropism of DENV, and hepatic encephalopathy from dengue hepatitis
  • Dengue encephalitis: rarer; direct DENV CNS invasion with viral detection in CSF
  • Guillain-Barré syndrome (GBS): post-infectious; demyelinating neuropathy; multiple case series
  • Transitory Parkinsonism: rare; reversible parkinsonian features in the post-acute phase
  • Dengue-related maculopathy: visual disturbance (blurring, scotoma) occurring during or after dengue; may persist; associated with retinal haemorrhage and foveal oedema

Renal complications

  • Acute kidney injury (AKI) during DHF/DSS from hypoperfusion
  • Glomerulonephritis (immune complex-mediated)
  • Haemolytic uraemic syndrome (HUS): rare

Haematological complications

  • Haemophagocytic lymphohistiocytosis (HLH): macrophage activation syndrome triggered by dengue; potentially fatal; important to distinguish from primary dengue thrombocytopenia

Shih2023: Long-term Autoimmune Disease Incidence After Dengue

Shih2023 - Autoimmune Disease Risk After Dengue directly addresses whether dengue causes lasting autoimmune diseases. In a population-based cohort of 63,814 lab-confirmed dengue patients in Taiwan followed for a mean of 4.57 years, most autoimmune diseases showed no elevated incidence. Key findings for the post-dengue syndrome picture:

  • Autoimmune encephalomyelitis (ADEM) was the only disease with a robust post-dengue risk, and it was confined to the first month after symptom onset (HR >9999 in month 1; non-significant thereafter). This complication is acute, not a long-term sequela.
  • The overall autoimmune disease incidence was marginally elevated (aHR 1.16) but the clinical significance of this modest effect is uncertain.
  • Diseases previously hypothesised as post-dengue sequelae — SLE, post-infectious arthritis, GBS, myasthenia gravis — were non-significant at the population level.
  • This is important context for interpreting Garcia2009’s autoimmune marker findings: the elevated ANA (23.1%), IC, and CRP at 2 years post-dengue do not appear to translate into clinical autoimmune disease incidence at the population level.

Contradictions & Debates

  • The autoimmune marker findings in Garcia2009 (elevated ANA, IC, CRP at 2 years) appear to contradict Shih2023’s finding of no elevated clinical autoimmune disease incidence. Potential reconciliations: (1) most ANA/IC elevations are subclinical and self-resolving; (2) Garcia2009’s cohort was a highly selected symptomatic subset with multiple prior infections, not representative of all dengue patients; (3) ANA positivity is not equivalent to autoimmune disease.
  • Seet2007 reports fatigue at only 2 months post-discharge — it is unknown whether these patients continued to have fatigue at 6 months or 2 years, or whether the 2-month fatigue cohort represents the same patient population that would develop the longer-term autoimmune and musculoskeletal sequelae described in Garcia2009. The two studies measure different windows with no overlap.
  • Whether symptoms resolve beyond 2 years or persist longer is unknown from available evidence.
  • Guzman2016’s complication data are drawn from case reports and case series; systematic prevalence estimates for most complications (GBS, HLH, maculopathy) in dengue are not yet available.
  • The risk factor profiles of Seet2007 and Garcia2009 partially overlap (female sex as protective predictor in both) but are not identical — Garcia2009 identifies FcγRIIa-HH genotype and high IgG titres, while Seet2007 identifies chills and absence of rashes as acute-phase predictors. These may represent different phases of the same syndrome or different syndrome subtypes.

Sources

Graph View

Backlinks